PASG - Rasio kapitalisasi pasar marang pendapatan Passage Bio Inc.
Passage Bio, Inc. (PASG) relies on AAV vector patents and powerful lobbying under strict FDA oversight. Therapy safety is ensured by cryogenic supply chain logistics. Narrow CNS niches create a defensive moat, despite the binary risks of clinical trials. The current P/S ratio visualizes these fundamentals, while the value determines the metric's magnitude, capturing valuation deviations from the norm.
Passage Bio, Inc. (PASG) - rincian metrik lan laporan keuangan
- kuotasi saiki lan rata-rata prakiraan nilai:
- statistik kapitalisasi pasar:
- indikator kapitalisasi buku:
- statistik kawajiban utang lan likuiditas:
Utang marang Modal Passage Bio, Inc.|PASG - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal passagebio.com|PASG - Gunggung utang perusahaan|Utang-utang marang aset resik Passage Bio Corp|PASG - Utang jangka dawa perusahaan|Tanggungan utang jangka cendhak perusahaan Passage Bio|Indikator likuiditas cepet passagebio.com
- rincian asil keuangan lan kelipatan valuasi:
PASG - Penghasilan resik|Prakiraan bathi perusahaan Passage Bio, Inc.|PASG - Rasio rega marang bathi|Rasio rega marang bathi sing dikarepake passagebio.com|PASG - Pangali PEG|Pangali EV/EBITDA Passage Bio Corp|PASG - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone patang kuartal pungkasan Passage Bio|PASG - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham sajroning taun lumaku passagebio.com|PASG - Wutah bathi saben saham ing taun lumaku|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep Passage Bio, Inc.
- rincian pendapatan lan dodolan emiten:
Analisis umum perusahaan:PASG, Passage Bio Inc.
An investment audit of the issuer requires a thorough assessment of market value relative to actual earnings before purchasing assets. This metric is calculated as the ratio of Passage Bio, Inc. (PASG) market capitalization to its total revenue, measuring the premium the market is willing to pay per unit of sales. For this gene therapy developer, this ratio reflects the risks of commercialization delays caused by geopolitical barriers in clinical trials. Analyzing the price-to-sales ratio allows for a balance between expected returns and regulatory threats.
Pesaing Passage Bio, Inc.
BIIB - Rega marang dodolan|Neurocrine Biosciences, Inc. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan RGC|Axsome Therapeutics Inc - Multiplikator P/S|ACAD: Rasio rega marang pendapatan|XENE: Multiplikator P/S|VKTX - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Supernus|Rega marang dodolan Catalyst Pharma CPRX|Kapitalisasi marang pendapatan DNLI (Denali Therapeutics Inc)|HRMY (Harmony Corp) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S BHVN (Biohaven Ltd.)|Koefisien rega marang pendapatan amylyx.com (AMLX)|TRVI - Rasio rega marang pendapatan|PRAX (Praxis Precision Medicines Inc) - Rasio kapitalisasi marang pendapatan|AVXL: Multiplikator P/S|Kapitalisasi marang pendapatan CeriBell EEG|Kapitalisasi marang pendapatan PRTA|Alector Therapeutics (ALEC) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Annexon (ANNX)|OMER: Rasio rega marang dodolan|Multiplikator P/S NGNE (Neurogene Corp)|Multiplikator P/S AC Immune Inc ACIU|VYGR - Rasio rega marang pendapatan|Koefisien rega marang pendapatan neumoratx.com NMRA|SCLX: Multiplikator P/S|Multiplikator rega marang pendapatan Tevogen Bio Holdings Inc. TVGN|Rasio rega marang pendapatan Alpha Cognition Inc|Rasio kapitalisasi marang pendapatan CGTX (Cognition Therapeutics Inc.)|Multiplikator P/S IKT|SAVA - Rega marang dodolan|Assertio - Kapitalisasi marang pendapatan|Multiplikator P/S Coya Therapeutics Inc COYA|VTGN - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan OVID (Ovid Therapeutics Inc.)|Acumen Pharmaceuticals (ABOS) - Rasio rega marang pendapatan|Rega marang dodolan cervomed.com (CRVO)|Rasio rega marang pendapatan Alterity Therapeutics Ltd.|Clene Nanomedicine - Rasio rega marang dodolan|Multiplikator P/S PEPG|Multiplikator P/S Jupiter Neurosciences, Inc. (JUNS)|Rasio rega marang pendapatan Relmada Therapeutics RLMD|Koefisien rega marang pendapatan annovisbio.com (ANVS)|GRCE - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Firefly Neuroscience, Inc. AIFF|KLTO: Multiplikator P/S|NeuroSense Therapeutics Ltd. (NRSN) - Multiplikator P/S|RVPH (Reviva Pharmaceuticals) - Multiplikator P/S|MTVA - Multiplikator rega marang pendapatan|Multiplikator P/S NRXS|HSDT - Rega marang dodolan|Neuphoria Therapeutics - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan NERV|Athira Pharma, Inc. - Multiplikator P/S|ADXN: Rasio rega marang pendapatan|ALZN: Multiplikator P/S|CYCN - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Protagenic Therapeutics Inc.|Rega marang dodolan Pasithea KTTA|Kapitalisasi marang pendapatan CRGT (Cortigent, Inc.)|ATXI (avenuetx.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S BCLI (BrainStorm Cell Therapeutics)|Koefisien rega marang pendapatan Cara Therapeutics Inc. (CARA)|CHRO - Rasio rega marang pendapatan|ELYM (Eliem Therapeutics) - Rasio kapitalisasi marang pendapatan|ITCI: Multiplikator P/S|Kapitalisasi marang pendapatan longboardpharma.com|Kapitalisasi marang pendapatan MRNS|NKGen Biotech Inc (NKGN) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan NeuroBo (NRBO)|SAGE: Rasio rega marang dodolan|Multiplikator P/S SNPX (Synaptogenix, Inc.)|Multiplikator P/S trevena.com TRVN|VIGL - Rasio rega marang pendapatan|Koefisien rega marang pendapatan anewmeds.com WENA|CERE: Multiplikator P/S
